glp1ledger

Medical Weight Loss: What the Programmes Sell, What It Costs, and What the Evidence Covers

What 'medical weight loss' programmes include — clinician visits, labs, prescriptions, coaching, clinic shots — with three online programmes' published prices and the evidence behind each part, read 16 November 2026.

Ronald R · Edited by Caroline S · Published 2026-11-16

Illustration: An empty medical examination room with a scale on a wooden floor, lit by natural light.
Illustration

"Medical weight loss" describes who runs a weight programme, not what it contains. The term has no legal definition. It covers a weight clinic in a strip mall, a hospital obesity service and an online subscription, and the bundle each one sells differs: a clinician visit, lab tests, a prescription, coaching, clinic-made injections, or some of these. This page separates the parts, says which are prescription medicines and which are clinic products, sets out the evidence behind each part and the prices three online programmes publish, and says what is not established. It names no programme as better than another.

Read on 16 November 2026 from the US Preventive Services Task Force, the Medicare Coverage Database, and the pricing pages of Found, Calibrate and Noom.

What a programme can include

Part What it is Prescription? Where the evidence is
Clinician visit An assessment by a doctor, nurse practitioner or physician assistant, in person or by video or text — Required before any prescription; see how a GLP-1 prescription happens
Lab tests Blood tests before or during treatment — Often billed separately or to insurance
Behavioural programme Diet, activity and habit coaching, usually many sessions No USPSTF review, below
Approved weight medicine Wegovy, Zepbound, Foundayo, the Wegovy pill, Saxenda, Contrave, Qsymia, phentermine, orlistat Yes Each drug's label and trials; see weight-loss pills and weight-loss injections
Compounded GLP-1 A pharmacy-made version of semaglutide or tirzepatide Yes, but not FDA-approved See compounded GLP-1s
Off-label medicine A drug approved for something else, such as metformin or topiramate Yes See metformin and topiramate
Clinic shots B12, "lipo" or "MIC" injections Usually pharmacy-made; none approved for weight See lipotropic injections
Supplements and meal products Shakes, bars, fibre capsules sold by the programme No See GLP-1 supplements

The line that matters most is between an approved medicine, which FDA has reviewed for the use on its label, a compounded or off-label medicine, which a clinician can prescribe but which has no approved weight indication in that form, and a clinic product, which is sold as part of the programme without an approval for weight loss at all. The same programme can sell all three.

What the evidence covers, part by part

Behavioural programmes. The US Preventive Services Task Force recommended on 18 September 2018, at grade B, that clinicians "offer or refer adults with a body mass index (BMI) of 30 or higher … to intensive, multicomponent behavioral interventions." Its evidence review pooled 67 trials with 22,065 people: at 12 to 18 months, the programme groups lost 2.39 kg (5.3 lb) more than control groups (95% CI −2.86 to −1.93), with wide variation between trials (I² 90%). Most programmes ran one to two years with 12 or more sessions in the first year. The Task Force notes that FDA treats a 5% weight loss as clinically important.

Medicines. The GLP-1 trials were run on top of counselling: in both arms of STEP 1 and SURMOUNT-1 participants received diet and activity advice. In adults with obesity and no diabetes, semaglutide 2.4 mg lowered weight by 14.9% against 2.4% on placebo over 68 weeks, and tirzepatide 15 mg by 20.9% against 3.1% over 72 weeks. The older medicines and their trial figures are on their own pages: the phentermine label record, Contrave, Qsymia, orlistat.

Clinic shots. For lipotropic, B12 and "MIC" injections sold for weight loss, our census found no approved application for weight and no human trial of the injections for weight; B12 is approved for deficiency. That record is on the lipotropic injections page.

The two sets of figures are not one ranking: the behavioural review measured kilograms against control in mixed adult populations, the drug trials measured percentage of body weight against placebo, with counselling in both arms.

What Medicare pays for

Medicare's National Coverage Determination 210.12, effective for services on or after 29 November 2011, covers intensive behavioural therapy for obesity, defined as a BMI of 30 or higher. It must be given by a qualified primary care practitioner in a primary care setting, and it follows the Task Force's "5-A" counselling framework. The covered schedule:

  • one face-to-face visit every week for the first month;
  • one every other week for months 2 to 6;
  • one a month for months 7 to 12, only if the person has lost at least 3 kg in the first six months, as documented at the six-month reassessment.

That is the counselling part. Whether Medicare or a private plan pays for a weight-loss medicine is a separate rule, covered on does Medicare cover GLP-1s and GLP-1 insurance coverage.

What three online programmes publish as their price

Read from each programme's own pricing page on 16 November 2026. These are membership fees; what they include and leave out is stated as each seller states it.

Programme Published price What the seller says is not included, or costs more
Found Cash plans from $149 a month; insurance plans from $79 a month — "based on 12-month plans paid up-front", billed per 28-day cycle. Monthly plans from $269 (cash) or $199 (insurance) Insurance plans need video visits billed at a copay "typically around $30"; prescriptions at the clinician's discretion; price varies with medicine and coverage. Lists compounded semaglutide and tirzepatide among its medicines
Calibrate $199 a month, "initial 3-month commitment required" — $597 in total "Lab tests and prescription medications are not included in the membership cost"; GLP-1 copays for most commercially insured members "typically $25/month or less after any deductible is met"; a money-back offer tied to 10% weight loss, on its terms
Noom Microdose GLP-1 Rx programme "starting at $79, regardless of insurance"; access to brand-name medicines "starting at $39 plus any out-of-pocket cost for the medication itself" Medicine cost depends on insurance; prescriptions need a clinical evaluation

Three points sit in the small print rather than the headline. The lowest Found prices assume a year paid up front. Calibrate's fee excludes the medicine and the labs, so the total depends on insurance. Noom's $79 programme is a microdose programme; what microdosing a GLP-1 means, and what trials have tested at sub-label doses, is on GLP-1 microdosing. Noom's earlier prices and billing terms are on our Noom cost page. In-person clinic chains publish fewer prices online and were not read for this page; the medicines' own self-pay prices are on GLP-1 cost.

What is not established

  • No trial compares one commercial programme with another, so no published evidence says which programme produces more weight loss.
  • The behavioural evidence comes from trial programmes with set session counts; whether a given commercial programme delivers that intensity is not shown by its price page.
  • The membership prices above do not show what a year of treatment costs once medicines, labs and copays are added; that depends on the medicine and on insurance.
  • Whether a programme's clinic products (shots, supplements) add anything to its prescription medicines has not been tested in trials found for this page.

The decision about whether to join a programme, and which medicine if any, belongs with the person and their own clinician, who can weigh their health record, other medicines and insurance. This page reports what programmes sell and what the evidence covers; it does not recommend a programme, a clinic or a medicine.

Sources

  • US Preventive Services Task Force, "Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions", final recommendation statement, 18 September 2018 — uspreventiveservicestaskforce.org, read 16 November 2026.
  • Centers for Medicare & Medicaid Services, National Coverage Determination 210.12, Intensive Behavioral Therapy for Obesity — Medicare Coverage Database, read 16 November 2026.
  • Found, plans and pricing; Calibrate, pricing; Noom Med — read 16 November 2026.
  • Wilding JPH et al., NEJM 2021, PMID 33567185 (STEP 1). Jastreboff AM et al., NEJM 2022, PMID 35658024 (SURMOUNT-1).

Frequently asked questions

What is medical weight loss?

It is a label sellers use for weight programmes run or supervised by a doctor, nurse practitioner or physician assistant. There is no legal definition. A programme may include a clinician visit, lab tests, a prescription medicine, coaching on diet and activity, and sometimes clinic-made injections; which of these are included, and which cost extra, differs from seller to seller.

How much does medical weight loss cost?

It depends on what is bundled. On 16 November 2026 three online programmes published starting prices between $39 and $269, with medicines, labs or copays often charged on top: Found from $149 a month cash or $79 with insurance on a prepaid year, Calibrate $199 a month for at least three months with labs and medicines excluded, and Noom from $79 for its microdose programme or from $39 plus the medicine's cost for brand-name medicines. In-person clinic prices were not read for this page.

Does insurance or Medicare cover medical weight loss?

Parts of it can be covered. Medicare covers intensive behavioural therapy for obesity in primary care for people with a BMI of 30 or higher, with continued visits after six months only for those who have lost at least 3 kg. Coverage of weight-loss medicines is a separate question, set by each plan; it is covered on our Medicare and insurance pages.

Is medical weight loss better than a GLP-1 on its own?

The trials measured different things. Behavioural programmes produced about 2.4 kg more loss than control at 12 to 18 months across 67 trials; in the semaglutide and tirzepatide trials both arms also received diet and activity counselling, and the medicine groups lost about 15% and 21% of body weight against 2% to 3% on placebo. Which approach suits a person is a decision for that person and their clinician.

Are the B12 or lipo shots at weight-loss clinics a prescription medicine?

They are usually made up by a pharmacy or the clinic, and none is approved for weight loss. B12 injections are approved to treat B12 deficiency. Our lipotropic injections page sets out what these shots contain and what the record shows.